Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study

被引：0

作者：

Melisi, D. ^{[1
]}

Siveke, J. T. ^{[2
]}

Blanc, J. ^{[3
]}

Von Hoff, D. D. ^{[4
]}

Wang-Gillam, A. ^{[5
]}

Chen, L. ^{[6
]}

Becker, C. ^{[7
]}

Mamlouk, K. ^{[8
]}

De Jong, F. ^{[9
]}

Hubner, R. ^{[10
]}

机构：

[1] Univ Verona, Verona, Italy

[2] West German Canc Ctr, Essen, Germany

[3] Ctr Integral Oncol Clara Campal, Madrid, Spain

[4] TGen & Honor Hlth, Phoenix, AZ USA

[5] Washington Univ, St Louis, MO USA

[6] Natl Inst Canc Res, Tainen, Taiwan

[7] Merrimack Pharmaceut, Cambridge, England

[8] Baxalta Pharmaceut, Cambridge, England

[9] Baxalta Pharmaceut, Zurich, Switzerland

[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw333.4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B04

引用

页数：1

共 42 条

[1] Effects of nanoliposomal irinotecan (nal-IRI;MM-398) ± 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
Siveke, J. T.
Cubillo, A.
Blanc, J. -F
Melisi, D.
Von Hoff, D. D.
Wang-Gillam, A.
Chen, L. -T
Becker, C.
Mamlouk, K.
Belanger, B.
Yang, Y.
de Jong, F.
Hubner, R.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 259 - 259
[2] Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Chen, L-T.
Wang-Gillam, A.
Li, C-P.
Bodoky, G.
Dean, A.
Shan, Y-S.
Jameson, G. S.
Macarulla, T.
Lee, K-H.
Cunningham, D.
Blanc, J-F.
Hubner, R.
Chiu, C-F.
Schwartsmann, G.
Braiteh, F.
Belanger, B.
Bayever, E.
de Jong, F.
von Hoff, D. D.
Siveke, J. T.
ANNALS OF ONCOLOGY, 2016, 27
[3] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Chen, L. -T.
Siveke, J.
Wang-Gillam, A.
Hubner, R.
Pant, S.
Dragovich, T.
Chung, V.
Chang, D.
Ross, P.
Cooray, P.
Tebbutt, N.
Franke, F.
Belanger, B.
Dhindsa, N.
de Jong, F.
Mamlouk, K.
Von Hoff, D.
ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
[4] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew
Shan, Yang-Shen
Jameson, Gayle S.
Macarulla, Teresa
Lee, Kyung-Hun
Cunningham, David
Blanc, Jean-Frederic
Hubner, Richard
Chiu, Chang-Fang
Schwartsmann, Gilberto
Siveke, Jens T.
Braiteh, Fadi S.
Moyo, Victor M.
Belanger, Bruce
Bayever, Eliel
Von Hoff, Daniel D.
Chen, Li-Tzong
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[5] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine
Hubner, R.
Cubillo, A.
Blanc, J. -F.
Melisi, D.
Von Hoff, D.
Wang-Gillam, A.
Chen, L. -T.
Becker, C.
Mamlouk, K.
Belanger, B.
Yang, Y.
De Jong, F.
Siveke, J.
ANNALS OF ONCOLOGY, 2016, 27 : 119 - 119
[6] Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1
Hubner, R.
Cubillo, A.
Blanc, J-F.
Melisi, D.
von Hoff, D. D.
Wang-Gillam, A.
Chen, L-T.
Becker, C.
Mamlouk, K.
Belanger, B.
Yang, Y.
de Jong, F.
Siveke, J. T.
ANNALS OF ONCOLOGY, 2016, 27
[7] Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew
Shan, Yang-Shen
Jameson, Gayle S.
Macarulla, Teresa
Lee, Kyung-Hun
Cunningham, David
Blanc, Jean-Frederic
Hubner, Richard
Chiu, Chang-Fang
Schwartsmann, Gilberto
Siveke, Jens T.
Braiteh, Fadi S.
Moyo, Victor M.
Belanger, Bruce
Bayever, Eliel
Von Hoff, Daniel D.
Chen, Li-Tzong
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
Pelzer, U.
Blanc, J. -F
Melisi, D.
Cubillo, A.
Von Hoff, D. D.
Wang-Gillam, A.
Chen, L. -T
Siveke, J. T.
Wan, Y.
Solem, C. T.
Botteman, M.
Yang, Y.
de Jong, F.
Hubner, R.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 260 - 260
[9] Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Hubner, R. A.
Chen, L-T.
Siveke, J. T.
Li, C-P.
Bodoky, G.
Dean, A.
Shan, Y-S.
Jameson, G. S.
Macarulla, T.
Lee, K-H.
Cunningham, D.
Blanc, J-F.
Chiu, C-F.
Schwartsmann, G.
Braiteh, F.
Mamlouk, K.
Belanger, B.
de Jong, F.
von Hoff, D. D.
Wang-Gillam, A.
ANNALS OF ONCOLOGY, 2016, 27
[10] Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Siveke, J. T.
Chen, L-T
Von Hoff, D. D.
Li, C-P
Wang-Gillam, A.
Bodoky, G.
Dean, A.
Shan, Y-S
Jameson, G.
Macarulla, T.
Lee, K-H
Cunningham, D.
Blanc, J-F
Hubner, R. A.
Chiu, C-F
Schwartsmann, G.
Braiteh, F.
Moyo, V.
Belanger, B.
Bayever, E.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 170 - 170

← 1 2 3 4 5 →